Alzecure Pharma Ab · OMXSTO:ALZCUR

Alzecure Pharma Ab — Investor Presentation (May 2023)

19 slides from Alzecure Pharma Ab's investor presentation, May 17, 2023

1. Slide 1: Alzstatin: A preventive treatment against Alzheimer's - Background & Evolution

   May 17, 2023 Alzstatin® : A preventive treatment against Alzheime - Background & Evolution —, Johan Sandin, PhD, CSO, AlzeCure Pharma

2. Slide 2: Healthy brain vs Alzheimer's brain

   Healthy brain Alzheimer’s brain 2

3. Slide 3: Amyloid in healthy vs Alzheimer's brain

   A amyloid Healthy brain Alzheimer’s brain 3

4. Slide 4: Alzheimer's disease progression

   Alzstatin® – Gamma-Secretase Modulator  ALZHEIMER'S DISEASE PROGRESSION Pre-symptomatic Alzheimer Symptomatic Alzheimer 10-20 years 7-10 years Abnormal Area where the highest societal gains can be achieved, and which AlzeCure can cater to Aβ Amyloid Memory Tau Mediated Brain Injury & Structure Clin

5. Slide 5: Alzstatin modulates the enzyme, alters its cleaving pattern and limits aggregation

   Alzstatin® – gamma-secretase modulator  Alzstatin® modulates the enzyme, alter its cleaving pattern and thereby limits the aggregation Aggregation X X A42 - main culprit in Alzheimer progression Alzstatin® targets the gamma- secretase as a modulator - does not block enzyme activity 5

6. Slide 6: Antibodies bind and clear aggregated Aβ peptides

   Alzstatin® – Gamma-Secretase Modulator A Antibodies bind and clear aggregated A peptides. 6

7. Slide 7: GSMs inhibit the formation of all Aβ aggregates

   Alzstatin® – Gamma-Secretase Modulator Aβ X GSM’s inhibits the formation of all A aggregates 32 7 *) GSM = Gamma Secretase Modulator

8. Slide 8: GSMs increase formation of shorter protective Aβ fragments

   Alzstatin® – Gamma-Secretase Modulator Aβ X GSM’s increase formation of shorter protective A fragments 33 8 *) GSM = Gamma Secretase Modulator

9. Slide 9: Alzstatin - Gamma-Secretase Modulator

   Alzstatin® – Gamma-Secretase Modulator  34

10. Slide 10: Alzstatin reduces toxic Aβ42 and Aβ40, increases protective Aβ38 and Aβ37

    Alzstatin® – Gamma-Secretase Modulator  Alzstatin reduces toxic A42 and A40, while No effect on total A increasing protective A38 and A37 peptides Consistent with a GSM 10

11. Slide 11: Alzstatin potently reduces toxic brain Aβ42 in mice

    Alzstatin® – Gamma-Secretase Modulator 120 100 Control Control 80 GSI Semagacestat ( 1 uM) 60 40 GSM cmpd ACD678 (3 uM) 20 0 C99-GVP Notch1DE- EphB2-GVP EphA4-GVP GVP Other proteins that are cleaved by gamma-secretase 0 30 100 200 µmol/kg Alzstatin potently reduces the Alzstatin compounds do not aff

12. Slide 12: Small molecule therapy, oral formulation, early treatment

    Alzstatin® – Gamma-Secretase Modulator Small molecule therapy Oral formulation => Home treatment • Small molecules generally pass much more readily • Don’t need to go to the hospital once or twice a across the BBB to its target site - the brain month for an infusion of the drug • Provides a more cos

13. Slide 13: Clinical PoM and central target engagement already in Phase I

    Alzstatin® – Gamma-Secretase Modulator • Clinical PoM and central target engagement already in Phase I − SAD/MAD studies conducted in healthy volunteers − Evaluation of safety and tolerability after single and repeated administration − Possibility to explore biomarker effects showing central target

14. Slide 14: Preventive therapy and maintenance therapy

    Alzstatin® – Gamma-Secretase Modulator Preventive therapy based on genetic risk factors* and biomarkers • Early stand-alone treatment before onset of symptoms and any major neurodegeneration occurs • Prevents build-up of amyloid – an early pathological feature of AD • Suitable for preventive therapy

15. Slide 15: Preventive therapy and maintenance therapy

    Alzstatin® – Gamma-Secretase Modulator Preventive therapy based on genetic risk factors* and biomarkers • Early stand-alone treatment before onset of symptoms and any major neurodegeneration occurs • Prevents build-up of amyloid – an early pathological feature of AD • Suitable for preventive therapy

16. Slide 16: Main known competitors

    Alzstatin® – Gamma-Secretase Modulator Main known competitors: − UCSD-776890 (Steven Wagner)/NIH – Phase 1 − Roche RG6289 – Phase 1 Published data on Pfizer’s PF-06648671 show that GSM’s can display both potent efficacy and good safety in man. ➔ Development stage of Alzstatin in line with competitor

17. Slide 17: Advantages with Alzstatin

    Alzstatin® – Gamma-Secretase Modulator Advantages with Alzstatin ✓ Reduces amyloidogenic Aβ42 production ✓ Increase the shorter peptides Aβ37 and Aβ38 - suggested to have protective properties ✓ Do not affect the total amount of Aβ – thus any physiological function likely not affected ✓ Mode of acti

18. Slide 18: Team at AlzeCure Pharma and academic collaborators

    • Team at Alzecure Pharma • Karolinska Institutet − Gunnar Nordvall − Prof. Bengt Winblad − Boel Nilsson − Assoc. Prof. Lars Tjernberg − Maria Backlund − Azita Rasti • Göteborgs Universitet − Märta Dahlström − Prof. Henrik Zetterberg − Magnus Halldin − Lotta Agholme, PhD − Veronica Lidell − Stefanie

19. Slide 19: AlzeCure Pharma AB contact details

    AlzeCure Pharma AB Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm Sweden www.alzecurepharma.com info@alzecurepharma.com

AlzeCure Pharma — Investor Presentation (May 2023) on 6ix